相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Ravi Vij et al.
BLOOD (2012)
Aphase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S. Siegel et al.
BLOOD (2012)
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Andrzej J. Jakubowiak et al.
BLOOD (2012)
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
Ravi Vij et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
Melissa Alsina et al.
CLINICAL CANCER RESEARCH (2012)
Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis
Sue Ellen Verbrugge et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo
Ajita V. Singh et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Specific Cell-Permeable Inhibitor of Proteasome Trypsin-like Sites Selectively Sensitizes Myeloma Cells to Bortezomib and Carfilzomib
Anne C. Mirabella et al.
CHEMISTRY & BIOLOGY (2011)
Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)
D. J. Kuhn et al.
CURRENT CANCER DRUG TARGETS (2011)
Proteostenosis and plasma cell pathophysiology
Simone Cenci et al.
CURRENT OPINION IN CELL BIOLOGY (2011)
Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats
Jinfu Yang et al.
DRUG METABOLISM AND DISPOSITION (2011)
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau et al.
LANCET ONCOLOGY (2011)
p21WAF1/CIP1 Upregulation through the Stress Granule-Associated Protein CUGBP1 Confers Resistance to Bortezomib-Mediated Apoptosis
Cristina Gareau et al.
PLOS ONE (2011)
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
Sara Bringhen et al.
BLOOD (2010)
Characterization of bortezomib-adapted I-45 mesothelioma cells
Lidong Zhang et al.
MOLECULAR CANCER (2010)
Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress
M. Ri et al.
LEUKEMIA (2010)
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
Deborah J. Kuhn et al.
BLOOD (2009)
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
Giada Bianchi et al.
BLOOD (2009)
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
Francesco Parlati et al.
BLOOD (2009)
Selective Inhibitor of Proteasome's Caspase-like Sites Sensitizes Cells to Specific Inhibition of Chymotrypsin-like Sites
Matthew Britton et al.
CHEMISTRY & BIOLOGY (2009)
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
Owen A. O'Connor et al.
CLINICAL CANCER RESEARCH (2009)
Effect of the CYP3A Inhibitor Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Advanced Solid Tumors: A Prospective, Multicenter, Open-Label, Randomized, Two-Way Crossover Drug-Drug Interaction Study
Karthik Venkatakrishnan et al.
CLINICAL THERAPEUTICS (2009)
Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma
D. Gutman et al.
LEUKEMIA (2009)
Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells
T. Rueckrich et al.
LEUKEMIA (2009)
Molecular basis of bortezomib resistance:: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
Ruud Oerlemans et al.
BLOOD (2008)
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer
Bruce D. Dorsey et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Point mutation of the proteasome β5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line
Shuqing Lu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Histione H2A monoubiquitination represses transcription by inhibiting RNA polymerase II transcriptional elongation
Wenlai Zhou et al.
MOLECULAR CELL (2008)
Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells
Dominik Fuchs et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2008)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
LMP2-specific inhibitors: Chemical genetic tools for proteasome biology
Yik Khuan (Abby) Ho et al.
CHEMISTRY & BIOLOGY (2007)
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition
Silke Meister et al.
CANCER RESEARCH (2007)
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
Regulation of DNA repair by ubiquitylation
TT Huang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Regulation of monoubiquitinated PCNA by DUB autocleavage
TT Huang et al.
NATURE CELL BIOLOGY (2006)
Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate
AF Kisselev et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome
M Groll et al.
STRUCTURE (2006)
Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib
V Uttamsingh et al.
DRUG METABOLISM AND DISPOSITION (2005)
The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway
SMB Nijman et al.
MOLECULAR CELL (2005)
Proteasome inhibition as a novel therapeutic target in human cancer
SV Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro
IR Garrett et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
NF-κB as a therapeutic target in multiple myeloma
T Hideshima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins
S Polo et al.
NATURE (2002)
Intracellular signaling from the endoplasmic reticulum to the nucleus: the unfolded protein response in yeast and mammals
C Patil et al.
CURRENT OPINION IN CELL BIOLOGY (2001)
Antigen processing by the proteasome
PM Kloetzel
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bc12 and perturbing the cellular redox state
KD McCullough et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
PERK mediates cell-cycle exit during the mammalian unfolded protein response
JW Brewer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex
M Orlowski et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2000)
Perk is essential for translational regulation and cell survival during the unfolded protein response
HP Harding et al.
MOLECULAR CELL (2000)
Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of α′,β′-epoxyketone proteasome inhibitors
M Groll et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2000)
分享论文
